Renal Anemia

Conflicts and Controversies

Nonfiction, Health & Well Being, Medical, Specialties, Internal Medicine, Nephrology, Hematology
Cover of the book Renal Anemia by , Springer Netherlands
View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart
Author: ISBN: 9789401599986
Publisher: Springer Netherlands Publication: June 29, 2013
Imprint: Springer Language: English
Author:
ISBN: 9789401599986
Publisher: Springer Netherlands
Publication: June 29, 2013
Imprint: Springer
Language: English

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

View on Amazon View on AbeBooks View on Kobo View on B.Depository View on eBay View on Walmart

Is the nephrology community facilitating excess cardiovascular deaths in patients with kidney failure and anemia by treating to a subnormal hematocrit? Why have clinicians and nephrologists permitted health insurance companies and the government to decide when anemia therapy should begin in persons with progressive kidney failure? Is iron the only variable that can be manipulated to maximize response to recombinant erythropoietin? Are we using too much intravenous iron in kidney failure patients, and is oral iron supplementation worthless in sustaining iron stores during long-term erythropoietin treatment? When does left ventricular hypertrophy begin to emerge in patients with progressive renal disease and is there convincing evidence that anemia is a significant cause of LVH in this setting? Is darbepoetin alfa, a new novel, long-acting erythropoietin, really superior to recombinant erythropoietin? This book is a compilation of proceedings from a conference in Brooklyn convened to address these and other controversial and unresolved issues in renal anemia management.

More books from Springer Netherlands

Cover of the book Ethica Dialectica by
Cover of the book Causality, Method, and Modality by
Cover of the book Explanation, Causation and Deduction by
Cover of the book Studies of Mind and Brain by
Cover of the book Phenomenology and Ontology by
Cover of the book Interdependencies Between Fertility and Women's Labour Supply by
Cover of the book Immigrants in Regional Labour Markets of Host Nations by
Cover of the book Landscape Indicators by
Cover of the book Minesite Recultivation by
Cover of the book Migration and Labor Market Adjustment by
Cover of the book Superintendent Performance Evaluation: Current Practice and Directions for Improvement by
Cover of the book Sustainable Phosphorus Management by
Cover of the book The Machines of Sex Research by
Cover of the book Compounding in Modern Greek by
Cover of the book Sociology Faces Pessimism by
We use our own "cookies" and third party cookies to improve services and to see statistical information. By using this website, you agree to our Privacy Policy